Each year, approximately 50,000 IVF cycles are performed in Vietnam, making the country one of the fastest-growing IVF markets in the region. However, alongside this growth come increasingly evident challenges: how to improve success rates, reduce the number of embryo transfers, optimize treatment costs, and—most importantly—ensure the long-term birth of healthy babies. Advanced genetic solutions are playing a pivotal role, laying the foundation for modern, precise, and sustainable reproductive medicine. IVF success rates vary by center and patient age; they are commonly reported at around 40–50% in younger patient groups and decline significantly with increasing maternal age, as well as other influencing factors such as oocyte and sperm quality, endometrial conditions, and embryo quality.
Preimplantation Genetic Testing (PGT) has become one of the most important tools for enhancing the quality of IVF treatment. PGT enables genetic evaluation of embryos prior to uterine transfer, thereby supporting the selection of embryos with high implantation potential and reducing the risk of genetic abnormalities. At EUROFINS GENTIS, a comprehensive PGT testing system—including PGT-A, PGT-SR, PGT-M, PGT-NEXT, and PGT-UPGRADE—is implemented in an integrated manner, providing physicians and patients with stronger scientific evidence to select optimal embryos, minimize risks, and improve IVF success rates.
PGT-M – Protecting future generations from monogenic genetic disorders
In addition to chromosomal abnormalities, monogenic genetic disorders continue to silently affect the health and happiness of many Vietnamese families. These conditions are often detected only after birth, leading to long-term treatment burdens and significantly impacting the quality of life of families and society as a whole.
Prof. Dr. Nguyen Dinh Tao (Chairman of Hanoi Assisted Reproduction) has highlighted PGT-M at EUROFINS GENTIS as a pioneering solution in early genetic disease prevention strategies. He noted that PGT-M enables accurate detection of known disease-causing mutations identified in parents or within families, allowing for the screening and selection of unaffected embryos prior to transfer. A key strength of PGT-M at EUROFINS GENTIS lies in its closed-loop and highly individualized process, which includes in-depth genetic counseling, identification of disease-related mutations, tailored test strategy design, and embryo genetic analysis using next-generation sequencing (NGS) technology. This solution can be applied to a wide range of genetic disorders, including rare diseases, opening opportunities for healthy childbirth among high-risk couples. Beyond its clinical value in establishing pregnancies unaffected by specific inherited traits—such as known pathogenic variants carried by one or both parents—PGT-M also helps reduce long-term treatment burdens, lower societal healthcare costs, and improve overall population health.
PGT-AI – AI breakthroughs in reproductive genetics
Alongside rapid advances in digital technology, artificial intelligence (AI) and bioinformatics are driving profound changes in reproductive medicine. Beyond genetic data analysis alone, AI enables the integration of multiple data sources—such as embryo imaging, molecular biology data, and clinical factors—thereby generating more accurate predictive models of embryo implantation potential and developmental outcomes.
Speaking at the HASAM 2025 conference, Dr. Pham Dinh Minh (R&D Director, EUROFINS GENTIS) introduced a new test researched and piloted by EUROFINS GENTIS: PGT-AI (icOne)—an advanced AI algorithm certified by the FDA, enabling in-depth analysis of embryo genetic data using modern machine learning platforms. This technology overcomes limitations of traditional PGT methods and supports more precise and personalized clinical decision-making for each patient.
Dr. Minh further noted that EUROFINS GENTIS is currently the exclusive partner implementing PGT-AI (icOne) in Vietnam, marking a significant milestone in bringing world-leading medical technologies closer to domestic patients. The combination of AI, bioinformatics, and the extensive expertise of specialist teams has enhanced IVF effectiveness while optimizing treatment costs and patient experience.
International quality management systems – The foundation for PGT accuracy
In reproductive genetics, particularly PGT testing, quality management systems play a decisive role in ensuring accuracy and reliability of results, directly influencing embryo selection, IVF treatment outcomes, and the future of each family. According to Dr. Nguyen Quang Vinh (Laboratory Director, EUROFINS GENTIS): “The comprehensive quality management system at EUROFINS GENTIS is built and operated in accordance with strict international standards such as ISO 15189, CAP, and CLSI. This ensures standardization across the entire PGT testing workflow—from receiving embryo biopsy samples, DNA processing, NGS and bioinformatics data analysis, to final reporting. Rigorous control at every step not only minimizes technical errors and ensures consistency and reproducibility of results, but also enhances safety, data security, and traceability, thereby supporting more accurate clinical decision-making.”
Together with internationally accredited laboratories, strict DNA contamination control environments, and highly experienced experts, EUROFINS GENTIS maintains high reliability in PGT testing while establishing a solid foundation for implementing advanced technologies such as PGT-AI—contributing to improved IVF outcomes and strengthening the trust of IVF centers and patients nationwide.
Accompanying the journey to parenthood
Guided by science, technology, and quality, EUROFINS GENTIS not only provides advanced genetic testing services but also serves as a trusted partner to IVF centers and Vietnamese families on their journey toward parenthood. Through the application of modern genetic technologies, EUROFINS GENTIS is steadily contributing to higher IVF success rates, early prevention of genetic diseases, and the sustainable development of reproductive medicine in Vietnam.
